Honokiol Antagonizes Doxorubicin Resistance in Human Breast Cancer Via MiR-188-5p/FBXW7/c-Myc Pathway

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2021 Feb 5

PMID 33544209

Citations 17

Authors

Xianglan Yi

Liping Lou

Jun Wang

Jing Xiong

Sheng Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Honokiol, a natural phenolic compound derived from Magnolia plants, is a promising anti-tumor compound that exerts a wide range of anti-cancer effects. Herein, we investigated the effect of honokiol on doxorubicin resistance in breast cancer.

Methods: Doxorubicin-sensitive (MCF-7 and MDA-MB-231) and doxorubicin-resistant (MCF-7/ADR and MDA-MB-231/ADR) breast cancer cell lines were treated with doxorubicin in the absence or presence of honokiol; then, the following tests were performed: flow cytometry for cell apoptosis, WST-1 assay for cell viability, qPCR and western blot for the expression of miR-188-5p, FBXW7, and c-Myc. MiR-188-5p mimic, miR-188-5p inhibitor, siFBXW7, and c-Myc plasmids were transfected into cancer cells to evaluate whether miR-188-5p and FBXW7/c-Myc signaling are involved in the effect of honokiol on doxorubicin resistance in breast cancer. A dual luciferase reporter system was used to study the direct interaction between miR-188-5p and FBXW7.

Results: Honokiol sensitized doxorubicin-resistant breast cancer cells to doxorubicin-induced apoptosis. Mechanically, upregulation of miR-188-5p was associated with doxorubicin resistance, and honokiol enhanced doxorubicin sensitivity by downregulating miR-188-5p. FBXW7 was confirmed to be a direct target gene of miR-188-5p. FBXW7/c-Myc signaling was involved in the chemosensitization effect of honokiol. Honokiol induced apoptosis in MCF-7/ADR and MDA-MB-231/ADR cells. However, FBXW7 silencing or c-Myc transfection resulted in resistance to the honokiol-induced apoptotic effect.

Conclusion: These findings suggest that downregulation of miR-188-5p by honokiol enhances doxorubicin sensitivity through FBXW7/c-Myc signaling in human breast cancer. Our study finds an important role of miR-188-5p in the development of doxorubicin resistance in breast cancer, and enriches our understanding of the mechanism of action of honokiol in cancer therapy.

Citing Articles

STYX Interacts with FBXW7 to Promote AML Proliferation via Inhibiting the Ubiquitination of CCNE1.

Yang R, Ning J, Wang H, Ma H, Cui L Cell Biochem Biophys. 2025; .

PMID: 39962032 DOI: 10.1007/s12013-025-01692-8.

Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy: ABCA/P53/C-myc crosstalk.

Abdel-Megeed R, Abdel-Hamid A, Kadry M Future Sci OA. 2024; 10(1):FSO979.

PMID: 38827789 PMC: 11140649. DOI: 10.2144/fsoa-2023-0107.

The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer.

Puskulluoglu M, Michalak I Front Pharmacol. 2024; 15:1349242.

PMID: 38500769 PMC: 10944949. DOI: 10.3389/fphar.2024.1349242.

FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies.

Wang W, Jiang K, Liu X, Li J, Zhou W, Wang C Front Pharmacol. 2023; 14:1278056.

PMID: 38027013 PMC: 10680170. DOI: 10.3389/fphar.2023.1278056.

miRNAs as short non-coding RNAs in regulating doxorubicin resistance.

Mirzaei S, Paskeh M, Moghadam F, Entezari M, Koohpar Z, Hejazi E J Cell Commun Signal. 2023; 17(4):1181-1202.

PMID: 38019354 PMC: 10713513. DOI: 10.1007/s12079-023-00789-0.

References

Samanta D, Park Y, Ni X, Li H, Zahnow C, Gabrielson E . Chemotherapy induces enrichment of CD47/CD73/PDL1 immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018; 115(6):E1239-E1248. PMC: 5819443. DOI: 10.1073/pnas.1718197115. View

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L . MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell. 2015; 28(1):129-40. PMC: 4518499. DOI: 10.1016/j.ccell.2015.06.001. View

Hancock B, Chen Y, Solzak J, Ahmad M, Wedge D, Brinza D . Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Res. 2019; 21(1):87. PMC: 6683504. DOI: 10.1186/s13058-019-1171-7. View

Welcker M, Clurman B . FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007; 8(2):83-93. DOI: 10.1038/nrc2290. View

King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P . The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 2013; 153(7):1552-66. PMC: 4146439. DOI: 10.1016/j.cell.2013.05.041. View

Sato M, Rodriguez-Barrueco R, Yu J, Do C, Silva J, Gautier J . MYC is a critical target of FBXW7. Oncotarget. 2015; 6(5):3292-305. PMC: 4413654. DOI: 10.18632/oncotarget.3203. View

Sailo B, Banik K, Girisa S, Bordoloi D, Fan L, Halim C . FBXW7 in Cancer: What Has Been Unraveled Thus Far?. Cancers (Basel). 2019; 11(2). PMC: 6406609. DOI: 10.3390/cancers11020246. View

Kim H, Woolard K, Lai C, Bauer P, Maric D, Song H . Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Cancer Res. 2012; 72(22):6065-75. DOI: 10.1158/0008-5472.CAN-12-2594. View

10.

Zhao D, Zheng H, Zhou Z, Chen C . The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010; 70(11):4728-38. DOI: 10.1158/0008-5472.CAN-10-0040. View

11.

Ma L, Liang Z, Zhou K, Zhou H, Qu L . 27-Hydroxycholesterol increases Myc protein stability via suppressing PP2A, SCP1 and FBW7 transcription in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2016; 480(3):328-333. DOI: 10.1016/j.bbrc.2016.10.038. View

12.

Cheng Y, Li G . Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2011; 31(1-2):75-87. DOI: 10.1007/s10555-011-9330-z. View

13.

Gasca J, Flores M, Giraldez S, Ruiz-Borrego M, Tortolero M, Romero F . Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. Oncotarget. 2016; 7(33):52751-52765. PMC: 5288146. DOI: 10.18632/oncotarget.10481. View

14.

Cho W . OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6:60. PMC: 2098778. DOI: 10.1186/1476-4598-6-60. View

15.

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

16.

Lai X, Eberhardt M, Schmitz U, Vera J . Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic Acids Res. 2019; 47(15):7753-7766. PMC: 6735922. DOI: 10.1093/nar/gkz638. View

17.

Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W . MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer. Cells. 2019; 8(12). PMC: 6953059. DOI: 10.3390/cells8121492. View

18.

Zhu X, Qiu J, Zhang T, Yang Y, Guo S, Li T . MicroRNA-188-5p promotes apoptosis and inhibits cell proliferation of breast cancer cells via the MAPK signaling pathway by targeting Rap2c. J Cell Physiol. 2019; 235(3):2389-2402. DOI: 10.1002/jcp.29144. View

19.

Wang M, Zhang H, Yang F, Qiu R, Zhao X, Gong Z . miR-188-5p suppresses cellular proliferation and migration via IL6ST: A potential noninvasive diagnostic biomarker for breast cancer. J Cell Physiol. 2019; 235(5):4890-4901. DOI: 10.1002/jcp.29367. View

20.

Hamam R, Ali A, Alsaleh K, Kassem M, Alfayez M, Aldahmash A . microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 2016; 6:25997. PMC: 4867432. DOI: 10.1038/srep25997. View